Minoxidil is named as an intervention in 6 current clinical trials in our China, USA and India registers. 3 are recruiting patients now. The most common phase is Not applicable. The sponsor with the most trials is Shenzhen People's Hospital (2). The most-studied condition is Androgenetic Alopecia (AGA).
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Efficacy of Dihydroartemisinin for Treating Female Androgenetic Alopecia
NCT07012486 · ClinicalTrials.gov ↗ · Androgenetic Alopecia (AGA)
|
Phase EARLY_PHASE1 | Recruiting | Shanghai Zhongshan Hospital | China |
|
Topical Application of Lactobacillus Reuteri for Androgenetic Alopecia
NCT07370519 · ClinicalTrials.gov ↗ · Androgenetic Alopecia (AGA)
|
Phase 2 | Recruiting | Shenzhen People's Hospital | China |
|
A Study on the Treatment of Androgenetic Alopecia in Young Men With Umbilical Cord Mesenchymal Stem Cell Exosomes
NCT07203599 · ClinicalTrials.gov ↗ · Androgenic Alopecia
|
Phase 1/2 | Recruiting | Shenzhen People's Hospital | China |
|
A Study on the Efficacy and Safety of Microneedling for Male Androgenetic Alopecia
NCT07758400 · ClinicalTrials.gov ↗ · Androgenetic Alopecia
|
Not applicable | Not yet open | Cheng Zhou | China |
|
A Safety and Efficacy Study of PDFE-2304 Topical Solution for the Treatment of Androgenic Alopecia.
NCT07011485 · ClinicalTrials.gov ↗ · Alopecia, Androgenetic, Baldness, Androgenetic Alopecia (AGA)
|
Phase 2 | Active, closed | PDFE Pharma Innovations FZCO | India |
|
Effects of a Topical Serum Solution on Hair Characteristics
NCT07785869 · ClinicalTrials.gov ↗ · Hair Characteristics
|
Not applicable | Active, closed | Pacagen, Inc. | USA, China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Shenzhen People's Hospital | 2 |
| Pacagen, Inc. | 1 |
| PDFE Pharma Innovations FZCO | 1 |
| Shanghai Zhongshan Hospital | 1 |
| Cheng Zhou | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 5 | 3 |
| Clinical trials in USA | 1 | 0 |
| Clinical trials in India | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
6 current trials in our China, USA and India registers name Minoxidil as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 3 of the 6 trials are recruiting: 3 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Shenzhen People's Hospital (2), Pacagen, Inc (1), PDFE Pharma Innovations FZCO (1) and Shanghai Zhongshan Hospital (1), among 5 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Minoxidil works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Minoxidil works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Minoxidil (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.